Allogeneic Stem Cells Market Size, Share & Industry Analysis, By Cell Origin (Bone marrow stem cell, Peripheral blood stem cell, Cord blood stem cell), By Application (Cardiovascular disorders, Cancer, Immunological disorder, Other) And Regional Forecast, 2024-2032

Allogeneic stem cell is mainly associated with stem cell transplantation. It is a process where a patient receives a healthy blood forming stem cell from a related donor who is not identical twin of the patient or an unrelated donor who is genetically similar to the patient. Globally the demand for allogeneic stem cell market is growing rapidly owing to increase in the genomic research for therapeutic and diagnostic purpose by using the therapeutic potency of stem cell. According to American Cancer Society, Inc., by the end of 2017, an amount of 0.07 million batches of cord blood was collected for public use and even more than that was collected for private use. Thus, the huge amount of investment on research and development of stem cells and related studies will propel the growth of allogeneic stem cell market.

Rising prevalence of chronic disorders like cardiovascular diseases, cancer, etc., is driving the allogeneic stem cells market in a significant way. For instance, according to a report published by Globocan 2020, it was reported that till 2020 the total cancer cases were 19.2 million and maximum of them had undergone chemotherapy for their treatment. Also, it is observed that the radiation from chemotherapy can damage the existing stem cell, generating a demand for allogeneic stem cells transplantation. Also, according to a data by HRSA Blood Stem Cell, around 23.0 million potential donor were present in the registry in 2020. Thus, increasing number of stem cells donors and introduction of stem cell banking is a privilege for the allogeneic stem cell market.

However, some complications can be observed after the transplantation like despite suppressing the immune system of the patient it can consider the new stem cell as a foreign matter and stop the engrafting process which can be fatal. Also the immune system of the donor can attack the healthy cells of the receiver or the patient. This is called graft-versus-host-disease. Along with these complications the high cost of the process is also limiting the growth of allogeneic stem cells market during the forecast period.

Key Market Driver -

Rising prevalence of cardiovascular disorder, cancer and other chronic disorders

Key Market Restraint -

Risk of post-surgical complications and high cost of process to restrict the market

Key Players Covered:

The major companies in the allogeneic stem cells market includes CELGENE CORPORATION, Sangamo Therapeutics, MEDIPOST Co. Ltd., ANTEROGEN. CO. LTD., Vericel Corpoartion, Athersys, Inc., BrainStorm Cell Limited., Cellular Biomedicine Group, Catalent, Inc. and other players.

Key Insights

• Prevalence of Chronic diseases, by Key Regions/Country, 2020


• Technological Advancements in the Market


• Impact of COVID-19 on the Allogeneic Stem Cell Market


• Key Industry Development - Mergers and Acquisitions

Regional Analysis:

The global allogeneic stem cells market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America held a dominant share of the allogeneic stem cells market in 2020. The dominance is due to increasing number of allogeneic hematopoietic cell transplantation in the region.  For instance, according to the data published by the HRSA Blood Stem Cell, in 2018, a total of 0.02 million HCTs were performed in the U.S and out of these 22.0% were unrelated transplants and 19.0% were related transplants. The market in Europe is expected to grow at a significant CAGR owing to well-established healthcare infrastructure and increasing number of myeloid malignancies, lymphoid malignancies, solid tumors, and non-malignant disorders in developed European countries that is leading to increasing demand for allogeneic as well as autologous stem cell transplant. Asia Pacific is expected to grow at a higher CAGR during the forecast period owing to government financial support in healthcare advancement, and increasing number of patients suffering from cancer related disorders resulting in growing demand for stem cell transplantation. Latin America and Middle East & Africa are expected to register a comparatively lower CAGR during the forecast period owing to presence of huge underpenetrated market for the stem cells transplantation.

To gain extensive insights into the market, Request for Customization

Segmentation

Allogeneic Stem Cells Industry Developments

• In February 2020, Catalent, Inc., acquired MaSTherCell with an aim to add development and manufacturing capabilities of both autologous and allogeneic cell therapy to the company.


• In December 2018, Sangamo Therapeutics Inc., announced the completion of acquisition of TxCell by purchasing the outstanding ordinary shares which in terms help Sangamo to grow in Immunological Tolerance market.